Search - tctmd.com

Displaying 41 - 60 of 196

Sort: Relevancy | Date

Presentation TCT 2019

ACURATE neo: Features and Benefits for Optimized TAVR

Presenter: Helge Möllmann

September 27, 2019

Presentation TCT 2019

Complex and High-Bleeding Risk Patients: Why We Still Need DES Innovation

Presenter: Robert Yeh

September 27, 2019

Presentation TCT 2019

Fundamentals of Stent Design: The BP-DES Sweet Spot

Presenter: Aloke Finn

September 27, 2019

Presentation TCT 2019

Short and Optimal DAPT: Lessons From the EVOLVE SHORT-DAPT Late Breaking Science

Presenter: Ajay Kirtane

September 27, 2019

Presentation TCT 2019

Switch Therapies/ USE NOACs Instead of Coumadin

Presenter: Dominick Angiolillo

September 27, 2019

Presentation TCT 2019

Drop ASA/ REDUCE Duration

Presenter: Roxana Mehran

September 27, 2019

Presentation TCT 2019

EVOLVE/ LEADERS Short DAPT Programs

Presenter: Ajay Kirtane

September 27, 2019

Presentation TCT 2019

COBRA REDUCE / MASTER DAPT

Presenter: Robert Byrne

September 27, 2019

Presentation TCT 2019

COMBO REDUCE

Presenter: Giuseppe De Luca

September 27, 2019

Presentation TCT 2019

XIENCE/ ONYX Short DAPT Programs

Presenter: Mitchell Krucoff

September 27, 2019

Presentation TCT 2019

Clinical Trial Design in HBR Patients: Should Risk Scores Be Incoporated?

Presenter: Davide Capodanno

September 27, 2019

Presentation TCT 2019

Idenifying the High Bleeding Risk Patient: The ARC HBR Definitions

Presenter: Philip Urban

September 27, 2019

Presentation TCT 2019

Case Presentation: A Patient at High Bleeding Risk and CAD- Real Management Dilemmas

Presenter: Davide Cao, MD

September 27, 2019

Presentation TCT 2019

Welcome and Introductions

Presenter: Roxana Mehran

September 27, 2019

Presentation TCT 2019

Case #3: Transcatheter Tricuspid Therapy for Severe TR

Presenter: Christine Chung

September 25, 2019

Presentation TCT 2019

Case #2: Mitral Valve-in-MAC

Presenter: Stephanie El-Hajj

September 25, 2019

Presentation TCT 2019

Case #1: Complex TAVR ⁠— Bioprosthetic Valve Failure

Presenter: Maureen McKiernan

September 25, 2019

News Daily News

ISCHEMIA Patients: High Rates of Severe-to-Moderate Ischemia, Multivessel CAD

Michael O'Riordan

March 01, 2019

News Conference News AHA 2018

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

Michael O'Riordan

November 10, 2018

News Daily News

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Michael O'Riordan

November 01, 2018

Advertisement

ACURATE neo: Features and Benefits for Optimized TAVR

Complex and High-Bleeding Risk Patients: Why We Still Need DES Innovation

Fundamentals of Stent Design: The BP-DES Sweet Spot

Short and Optimal DAPT: Lessons From the EVOLVE SHORT-DAPT Late Breaking Science

Switch Therapies/ USE NOACs Instead of Coumadin

Drop ASA/ REDUCE Duration

EVOLVE/ LEADERS Short DAPT Programs

COBRA REDUCE / MASTER DAPT

COMBO REDUCE

XIENCE/ ONYX Short DAPT Programs

Clinical Trial Design in HBR Patients: Should Risk Scores Be Incoporated?

Idenifying the High Bleeding Risk Patient: The ARC HBR Definitions

Case Presentation: A Patient at High Bleeding Risk and CAD- Real Management Dilemmas

Welcome and Introductions

Case #3: Transcatheter Tricuspid Therapy for Severe TR

Case #2: Mitral Valve-in-MAC

Case #1: Complex TAVR ⁠— Bioprosthetic Valve Failure

ISCHEMIA Patients: High Rates of Severe-to-Moderate Ischemia, Multivessel CAD

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content